Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project

WD Travis, G Hunninghake, TE King Jr… - American journal of …, 2008 - atsjournals.org
Rationale: The 2002 American Thoracic Society/European Respiratory Society classification
of idiopathic interstitial pneumonias identified nonspecific interstitial pneumonia (NSIP) as a …

Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium

SD Nathan, OA Shlobin, N Weir, S Ahmad, JM Kaldjob… - Chest, 2011 - Elsevier
The American Thoracic Society and European Respiratory Society guidelines for the
diagnosis and treatment of idiopathic pulmonary fibrosis (IPF) have been published recently …

[HTML][HTML] Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

L Richeldi, RM Du Bois, G Raghu… - … England Journal of …, 2014 - Mass Medical Soc
Background Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that
targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of …

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

PW Noble, C Albera, WZ Bradford, U Costabel… - The Lancet, 2011 - thelancet.com
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …

An earlier and more confident diagnosis of idiopathic pulmonary fibrosis

RM Du Bois - European Respiratory Review, 2012 - Eur Respiratory Soc
A diagnosis of idiopathic pulmonary fibrosis (IPF) has serious implications for the affected
individuals, who have a 50% likelihood of dying within 2− 3 yrs, an outcome which is worse …

[HTML][HTML] Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

L Richeldi, U Costabel, M Selman… - … England Journal of …, 2011 - Mass Medical Soc
Background Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality
rate. Because the signaling pathways activated by several tyrosine kinase receptors have …

[HTML][HTML] A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis

MA Seibold, AL Wise, MC Speer… - … England Journal of …, 2011 - Mass Medical Soc
Background The mutations that have been implicated in pulmonary fibrosis account for only
a small proportion of the population risk. Methods Using a genomewide linkage scan, we …

Interstitial lung disease in systemic sclerosis: a simple staging system

NSL Goh, SR Desai, S Veeraraghavan… - American journal of …, 2008 - atsjournals.org
Rationale: In interstitial lung disease complicating systemic sclerosis (SSc-ILD), the optimal
prognostic use of baseline pulmonary function tests (PFTs) and high-resolution computed …

Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis

BC Willis, JM Liebler, K Luby-Phelps… - The American journal of …, 2005 - Elsevier
The hallmark of idiopathic pulmonary fibrosis (IPF) is the myofibroblast, the cellular origin of
which in the lung is unknown. We hypothesized that alveolar epithelial cells (AECs) may …

An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease

KC Meyer, G Raghu, RP Baughman… - American journal of …, 2012 - atsjournals.org
Background: The clinical utility of bronchoalveolar lavage fluid (BAL) cell analysis for the
diagnosis and management of patients with interstitial lung disease (ILD) has been a subject …